Journal article
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Abstract
BACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.
METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled …
Authors
Eikelboom JW; Jolly SS; Belley-Cote EP; Whitlock RP; Rangarajan S; Xu L; Heenan L; Bangdiwala SI; Luz Diaz M; Diaz R
Journal
The Lancet Respiratory Medicine, Vol. 10, No. J Med Virol 93 2021, pp. 1169–1177
Publisher
Elsevier
Publication Date
12 2022
DOI
10.1016/s2213-2600(22)00298-3
ISSN
2213-2600